Pfizer and BioNTech have announced, they have submitted the data of the phase 1 trials of the vaccine to the US FDA for the purpose of supporting the evaluation of a third dose or the booster dose of the novel corona virus vaccine for getting the license in the future, and the data of these trials is also going to be submitted to the European Medicines Agency (EMA) and several other drug regulators in up-coming weeks.
Albert Bourla, chairman and CEO of Pfizer said, the vaccination has been their most effective means of the prevention of the people from the novel corona virus infection, specifically with the hospitalizations and severe disease, and it has also profound the impact of the vaccine in protecting the lives of the people has been indisputable, and still with the continuous threat of the Delta Variant of the Novel corona virus, they all must remain vigilant against the corona virus.
He also said, the data, which they have seen till now is suggesting that, a third dose of their novel corona virus vaccine is responsible in eliciting the levels of the antibodies that has been significantly exceeding those levels, which were seen after the primary schedule of two corona virus vaccine doses.
Ugur Sahin, co-founder, CEO and managing director of BioNTech said, they have been continuously striving to stay at least one step ahead of the novel corona virus, and this is why, they are also focusing on the expansion of the access to their novel corona virus vaccines for the people across the world and they are also working on various approaches as a part of the company’s strategy for the purpose of addressing the corona virus and its variants in the future.
